NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.
March 13, 2026 — HeartBeam reports 2025 results after FDA clearance of its 12-lead ECG synthesis software, launching cardiac care tech with partnerships and AI advancements for remote monitoring.
March 13, 2026 — LIXTE Biotechnology expands ovarian clear cell cancer trial with MD Anderson & GSK for LB 100 combination therapy. Clinical results expected 2026 for innovative cancer treatment approach.
March 13, 2026 — Rocky River Orthodontics offers braces and Invisalign in Huntersville, NC, with personalized care for all ages. Learn about their advanced treatments and community-focused approach.
March 13, 2026 — Creative Biolabs advances mRNA therapeutics with LPP delivery tech for genetic diseases & antibody production. Breakthrough enables targeted treatments beyond vaccines.
March 13, 2026 — Creative Biolabs expands lipid-based delivery services with Ethosomes, Transfersomes & Transethosomes for enhanced skin penetration in pharmaceutical & cosmetic applications.
March 12, 2026 — Aclarion CEO Brent Ness attends LSI USA 2026 to promote Nociscan, an AI-driven platform using biomarkers to diagnose chronic low back pain precisely.
March 12, 2026 — Discover advanced orthodontic care at Park City Orthodontics in Heber City, UT, offering braces and Invisalign in a family-friendly environment for healthy, confident smiles.
March 12, 2026 — Park City Orthodontics offers advanced braces and Invisalign in Coalville, UT, with personalized care for all ages. Transform your smile with expert orthodontic services in a family-friendly environment.
March 12, 2026 — Park City Orthodontics provides advanced braces and Invisalign treatments in Park City, UT, with personalized care, flexible financing, and a friendly environment for all ages.
March 12, 2026 — California Governor Gavin Newsom breaks with federal health positions, backing science over controversial policies. This creates a West Coast alliance challenging federal authority on public health matters.
March 12, 2026 — Oragenics initiates Phase IIa trial for ONP-002 concussion treatment in Australia using proprietary intranasal delivery technology to bypass blood-brain barrier.
March 12, 2026 — Glafabra Therapeutics receives FDA Orphan Drug Designation for GT-GLA-S03 cell therapy for Fabry disease. Breakthrough treatment could replace 130 clinic visits with single dose.
March 12, 2026 — First Steps Developmental Services in Woburn, MA, announces immediate ABA therapy enrollment for children ages birth to 6, with no waitlist, play-based programs, and major insurance acceptance.
March 12, 2026 — GeoVax publishes peer-reviewed data on GEO-CM04S1, a dual-antigen COVID-19 vaccine designed for immunocompromised patients. Learn how it targets spike and nucleocapsid proteins for broader protection.
March 12, 2026 — NeOnc Technologies updates on NEO212 and NEO100 brain cancer therapies, with $16M funding and Phase 2 progress. Stonegate Capital Partners covers clinical advancements.
March 12, 2026 — The Dairy Alliance promotes National Nutrition Month with free recipes, nutrition toolkits, and community events highlighting dairy's health benefits for all ages, including lactose-free options.
March 12, 2026 — Liv Women & Ashunta Sheriff Beauty collaborate on Women's History Month campaign combining vaginal microbiome health with inclusive beauty innovation through pH-responsive Thermal Lip Gloss.
March 12, 2026 — Friendly Recovery Center publishes educational blog on antisocial personality disorder therapies, covering diagnostic characteristics, treatment approaches, and integrated care for trauma-related symptoms.
March 11, 2026 — BioStem Technologies announces Q4 and full-year 2025 financial results conference call on March 24, 2026, featuring CEO and CFO insights into regenerative medicine advancements.
March 11, 2026 — NeuroOne Medical Technologies to present at Oppenheimer Healthcare Conference on March 17, 2026, featuring updates on its OneRF platform for brain treatment and pain management.